14:28 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Merrimack discontinues pancreatic cancer candidate after Phase II miss

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) reported that first-line treatment with istiratumab (MM-141) missed the primary and secondary endpoints in the Phase II CARRIE trial to treat metastatic pancreatic cancer. The company said it will discontinue the...
19:31 , Jun 25, 2018 |  BC Extra  |  Clinical News

Merrimack falls on Phase II pancreatic cancer failure

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) lost $4.01 (44%) to $5.14 on Monday after reporting that first-line treatment with istiratumab (MM-141) missed the primary and secondary endpoints in the Phase II CARRIE trial to treat metastatic pancreatic...
17:43 , Mar 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Studies in mice suggest a peptide-based EPHA2 agonist conjugated to paclitaxel could help treat triple-negative breast cancer (TNBC). Conjugation of an EPHA2 agonist peptide to the generic chemotherapy paclitaxel and in vitro...
19:52 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

Stemline reports additional Phase II data for SL-701 in GBM

In November, Stemline Therapeutics Inc. (NASDAQ:STML) reported additional data from the two-stage Phase II STML-701-0114 trial of SL-701 as a second-line treatment of glioblastoma multiforme (GBM). Data were presented at the Society of Neuro-Oncology...
17:07 , Jun 9, 2017 |  BioCentury  |  Finance

Pedaling to the clinic

With lead candidate BT-1718 expected to enter the clinic this year, Bicycle Therapeutics Ltd. has padded its coffers with a £40 million ($51.3 million) series B to expand its pipeline of bicyclic peptides for cancer....
00:58 , Mar 30, 2017 |  BC Week In Review  |  Clinical News

MM-310: Ph I started

Merrimack began an open-label, U.S. Phase I trial to evaluate IV MM-310 on day 1 of each 21-day cycle. A dose-escalation part will determine the MTD of MM-310 alone in up to 34 patients. The...
21:22 , Jan 20, 2017 |  BC Extra  |  Financial News

Stemline raises $45M in follow-on

Stemline Therapeutics Inc. (NASDAQ:STML) raised $45 million through the sale of 4.5 million shares at $10 in a follow-on underwritten by Jefferies, Cowen, Ladenburg Thalmann, H.C. Wainwright, Roth Capital Partners, Joseph Gunnar and Aegis Capital....
22:17 , Jan 12, 2017 |  BC Week In Review  |  Company News

Merrimack, Ipsen deal

Ipsen will acquire the commercial business of Merrimack, including U.S. rights to Onivyde irinotecan and Merrimack’s generic doxorubicin product. The companies expect the deal to close this quarter. Merrimack markets Onivyde to treat metastatic pancreatic...
00:30 , Jan 10, 2017 |  BC Extra  |  Company News

Ipsen acquiring Merrimack's marketed products

Ipsen Group (Euronext:IPN; Pink:IPSE) is acquiring the commercial business of Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) for $575 million up front and up to $450 million in milestones. The deal includes U.S. rights to Onivyde irinotecan, as...
21:34 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

SL-701: Preliminary Ph II STML-701-0114 data

Preliminary data from 42 evaluable patients with relapsed or refractory GBM in stage 1 of the 2-stage, open-label, U.S. Phase II STML-701-0114 trial showed that second-line treatment with subcutaneous SL-701 plus GM-CSF and imiquimod led...